GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes

• Published in: Archives of toxicology Vol. 94; no. 6; pp. 2113 - 2130
• Main Authors: Karhu, S. Tuuli, Kinnunen, Sini M., Tölli, Marja, Välimäki, Mika J., Szabó, Zoltán, Talman, Virpi, Ruskoaho, Heikki
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2020; Springer Nature B.V
• Subjects: Biocompatibility; Biomedical and Life Sciences; Biomedicine; Brain natriuretic peptide; Cardiomyocytes; Cardiotoxicity; Caspase-3; Cell viability; Chronic toxicity; Congestive heart failure; Content management systems; Deoxyribonucleic acid; DNA; Doxorubicin; Environmental Health; Exposure; Occupational Medicine/Industrial Medicine; Organ Toxicity and Mechanisms; Pharmacology/Toxicology; Pluripotency; Stem cells; Toxicity; Ventricle; GATA4-targeted compounds; Transcription factors; Cardioprotective; Cardiotoxicity; Doxorubicin; Human induced pluripotent stem cell-derived cardiomyocytes

Doxorubicin is a widely used anticancer drug that causes dose-related cardiotoxicity. The exact mechanisms of doxorubicin toxicity are still unclear, partly because most in vitro studies have evaluated the effects of short-term high-dose doxorubicin treatments. Here, we developed an in vitro model o...